Impacto de la edad y de la comorbilidad en la supervivencia y toxicidad del paciente con cáncer de próstata irradiado
Ferrer González, Ferran; Casas Duran, Francesc; Biete Solà, Albert.
Med. clín (Ed. impr.)
; 125(4): 121-126, jun. 2005. tab, graf
Artículo en Es | IBECS (España) | ID: ibc-036682
Documentos relacionados
Partial prostate re-irradiation for the treatment of isolated local recurrence of prostate cancer in patients previously treated with primary external beam radiotherapy: short-term results of a monocentric study.
Prostate-specific antigen nadir within 1 year of radiotherapy combined with hormone therapy predicts cancer-specific mortality and biochemical recurrence-free survival in prostate cancer patients.
Comparison of outcomes in high-risk prostate cancer patients treated with low-/high-dose-rate brachytherapy plus external beam radiotherapy.
Selecting the optimal radiation modality in prostate cancer.
Elective nodal radiotherapy in prostate cancer.
The Comparative Outcomes of Radical Prostatectomy versus Radiotherapy for Nonmetastatic Prostate Cancer: A Longitudinal, Population-Based Analysis.
Association of radiotherapy for prostate cancer and second primary colorectal cancer: a US population-based analysis.
Case series on multiple prostate re-irradiation for locally recurrent prostate cancer: something ventured, something gained.
Time to second biochemical recurrence as a prognostic indicator in postprostatectomy patients who undergo salvage radiation therapy: An RTOG 9601 based post hoc analysis.
LDR brachytherapy offers superior tumor control to single-fraction HDR prostate brachytherapy: A prospective study.